William Bachinsky
YOU?
Author Swipe
View article: Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis
Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis Open
Patients with ISR of multiple stent layers had higher rates of adverse stent-related events compared with patients with single-layer ISR. Treatment with a paclitaxel-coated balloon led to greater absolute risk reduction in 1-year TLF among…
View article: The PERFORMANCE II Trial
The PERFORMANCE II Trial Open
The rate of major adverse events was extremely low, demonstrating the study system is a safe, effective, and durable treatment option for high-risk patients. (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery…
View article: Editor's Choice – Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study
Editor's Choice – Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study Open
The next generation low dose SurVeil PCB demonstrated excellent safety and efficacy up to twenty four months and was non-inferior to the IN.PACT Admiral PCB. (ClinicalTrials registration ID: NCT03241459).
View article: OR4-1 | In-hospital Results with Intravascular Lithotripsy in the Real-World: Outcomes from the ACC NCDR® CathPCI Registry®
OR4-1 | In-hospital Results with Intravascular Lithotripsy in the Real-World: Outcomes from the ACC NCDR® CathPCI Registry® Open
Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in the treatment of calcified coronary artery disease (CAD) in large trials and small 'real-world' observational studies. Evidence from a larger more complex coho…
View article: Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Open
Importance Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved for use in coronary circulation in the United St…
View article: Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial
Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial Open
The Disrupt PAD III RCT secondary endpoint of superior 1-year primary patency was achieved, confirming the consistent safety and effectiveness of IVL followed by DCB treatment to facilitate a durable approach for patients with heavily calc…
View article: Intravascular Lithotripsy for Peripheral Artery Calcification
Intravascular Lithotripsy for Peripheral Artery Calcification Open
IVL is an effective vessel preparation strategy that facilitates definitive endovascular treatment in calcified femoropopliteal arteries in patients with peripheral artery disease. (Shockwave Medical Peripheral Lithoplasty System Study for…
View article: Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent
Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent Open
Purpose: To report the clinical effect of a drug-eluting stent on femoropopliteal occlusive disease in patients with long lesions. Materials and Methods: The global IMPERIAL Long Lesion substudy ( ClinicalTrials.gov identifier NCT02574481)…
View article: Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease Open
Background: Drug-coated balloons (DCBs) are a predominant revascularization therapy for symptomatic femoropopliteal artery disease. Because of the differences in excipients, paclitaxel dose, and coating morphologies, varying clinical outco…
View article: One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study)
One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study) Open
OSPREY 12-month data showed satisfactory outcome of the Misago stent for the treatment of TASC type A and type B SFA lesions and appears to be comparable to recent stent trials. In addition, the lack of difference in outcome among races su…
View article: High-risk percutaneous coronary intervention in a patient with a single coronary artery presenting as STEMI and cardiogenic shock
High-risk percutaneous coronary intervention in a patient with a single coronary artery presenting as STEMI and cardiogenic shock Open
Cardiogenic shock due to ST elevation myocardial infarction in a patient with a single coronary artery involving the sole vessel is a rare presentation. This can be clinically and angiographically challenging. Proper recognition of the top…